Literature DB >> 31808482

Tuning a modular system - synthesis and characterisation of a boron-rich s-triazine-based carboxylic acid and amine bearing a galactopyranosyl moiety.

Martin Kellert1, Paul Hoppenz, Peter Lönnecke, Dennis J Worm, Bernd Riedl, Johannes Koebberling, Annette G Beck-Sickinger, Evamarie Hey-Hawkins.   

Abstract

Introduction of a bis(isopropylidene)-protected galactopyranosyl moiety in s-triazine-based boron-rich carboxylic acids and amines results in soluble and suitable coupling partners for tumour-selective biomolecules with applications as selective agents for boron neutron capture therapy (BNCT). Bearing either a carboxylic acid or primary amine as a functional group, these compounds are highly versatile and thus largely extend the possible coupling strategies with suitable biomolecules. Modification of the gastrin-releasing peptide receptor (GRPR) selective agonist [d-Phe6, β-Ala11, Ala13, Nle14]Bn(6-14) with the carboxylic acid derivative yielded a bioconjugate with an optimal receptor activation and internalisation profile. This demonstrates the great potential of this approach for the development of novel boron delivery agents.

Entities:  

Year:  2019        PMID: 31808482     DOI: 10.1039/c9dt04031e

Source DB:  PubMed          Journal:  Dalton Trans        ISSN: 1477-9226            Impact factor:   4.390


  2 in total

Review 1.  Carboranes as unique pharmacophores in antitumor medicinal chemistry.

Authors:  Yu Chen; Fukuan Du; Liyao Tang; Jinrun Xu; Yueshui Zhao; Xu Wu; Mingxing Li; Jing Shen; Qinglian Wen; Chi Hin Cho; Zhangang Xiao
Journal:  Mol Ther Oncolytics       Date:  2022-01-10       Impact factor: 7.200

2.  Aza-BODIPY: A New Vector for Enhanced Theranostic Boron Neutron Capture Therapy Applications.

Authors:  Ghadir Kalot; Amélie Godard; Benoît Busser; Jacques Pliquett; Mans Broekgaarden; Vincent Motto-Ros; Karl David Wegner; Ute Resch-Genger; Ulli Köster; Franck Denat; Jean-Luc Coll; Ewen Bodio; Christine Goze; Lucie Sancey
Journal:  Cells       Date:  2020-08-25       Impact factor: 6.600

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.